Excalipoint Therapeutics
ET
Active
· 2025Developing next-generation T-cell engager therapies for cancer and autoimmune diseases.
Excalipoint Therapeutics
Developing next-generation T-cell engager therapies for cancer and autoimmune diseases.
About
Excalipoint Therapeutics is a biotechnology company focused on developing next-generation T-cell engager (TCE) therapies. The company leverages proprietary technology platforms, including TOPAbody, T-Cell Immune Shield, and TCE Probody, to create highly differentiated treatments for solid tumors and autoimmune diseases.
Tags
Score Breakdown
38Traction
39Team
60Visibility
10Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Excalipoint Therapeutics do?
Excalipoint Therapeutics is a biotechnology company focused on developing next-generation T-cell engager (TCE) therapies. The company leverages proprietary technology platforms, including TOPAbody, T-Cell Immune Shield, and TCE Probody, to create highly differentiated treatments for solid tumors and autoimmune diseases.
How much funding has Excalipoint Therapeutics raised?
Excalipoint Therapeutics has raised a total of $69M in funding. The most recent round on record is Seed.
Where is Excalipoint Therapeutics headquartered?
Excalipoint Therapeutics is headquartered in Shanghai, China.
When was Excalipoint Therapeutics founded?
Excalipoint Therapeutics was founded in 2025.
What industry does Excalipoint Therapeutics operate in?
Excalipoint Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Oncology, Immunology.